WESTLAKE VILLAGE, Calif.,
June 3, 2021 /PRNewswire/ -- MannKind
Corporation (Nasdaq: MNKD), which focuses on the development of
innovative medicines for patients with endocrine and orphan lung
diseases, announced today that it will present a poster [Abstract
#654 / Topic AS09 – New Insulin Delivery Systems: Inhaled,
Transdermal, Implanted Devices] at the 14th
International Conference on Advanced Technologies & Treatments
for Diabetes (ATTD 2021) to be held virtually, June 2-5. The
poster presents a post hoc analysis from the STAT study that
demonstrates how Afrezza (Technosphere Insulin or TI) reduced
nocturnal hypoglycemia compared to insulin aspart in adult patients
with type 1 diabetes (T1D).
![MannKind (PRNewsfoto/MannKind Corporation) MannKind (PRNewsfoto/MannKind Corporation)](https://mma.prnewswire.com/media/1509441/Mannkind_Avatar_Logo.jpg)
"When the STAT study was completed, it advanced our
understanding of potential benefits of Afrezza for those living
with Type 1 diabetes overall," said Dr. Kevin Kaiserman, Vice President, Medical Affairs
and Safety of MannKind. "With this post hoc statistical analysis,
we divided the CGM data into day and night and showed that using
Technosphere Insulin versus aspart reduced Level 1 nocturnal
hypoglycemia by 62% and Level 2 by 78%."
The ultra-rapid appearance and clearance of TI – which more
closely mimics physiologic insulin compared with subcutaneous
insulin aspart – may contribute to these findings, although larger
studies are needed to confirm this hypothesis, Kaiserman
explained.
The STAT study was a four-week, investigator-led, collaborative,
open-label pilot study that included 60 patients with T1D on
multiple daily injections of aspart who were randomized to either
the control cohort using aspart (n=34) or the TI cohort (n=26).
Level 1 (<70 mg/dL) and Level 2 (<54 mg/dL)
hypoglycemia measures were obtained from continuous glucose
monitors (CGM). For purposes of the study, nighttime was defined as
12 am to 6 am.
The poster is authored by Janet K.
Snell-Bergeon, PhD; Halis K.
Akturk, MD; Anne Peters, MD;
Kevin Kaiserman, MD and Satish K. Garg – representing a collaboration
between the Barbara Davis Center for Diabetes (University of Colorado-Aurora), Keck School of
Medicine of USC, and MannKind.
About MannKind Corporation
MannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only inhaled
ultra-rapid-acting mealtime insulin in the United States, where it is available by
prescription from pharmacies nationwide. Afrezza is also available
by prescription in Brazil, where
it is commercialized by the Company's partner, Biomm
SA. MannKind was established in 1991, and is headquartered in
Westlake Village, Calif., with a
manufacturing and R&D facility based in Danbury, Conn. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.comhttp://www.mannkindcorp.com/ to learn
more.
Forward-looking Statements
This press release
contains forward-looking statements that involve risks and
uncertainties. Words such as "believes", "anticipates", "plans",
"expects", "intends", "will", "goal", "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon MannKind's current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that continued testing of
Afrezza may not yield successful results or results that are
consistent with earlier testing, and other risks detailed in
MannKind's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2020 and subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
AFREZZA and TECHNOSPHERE are registered trademarks of MannKind
Corporation.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mannkind-announces-data-presentation-at-14th-international-conference-on-advanced-technologies--treatments-for-diabetes-attd-2021-to-be-held-virtually-june-2-5-301304900.html
SOURCE MannKind Corporation